A comparative study of cefoselis and ceftazidime in chronic respiratory tract infections

Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Masamitsu Nakajima, Kenjiro Kikuchi, Yoshinobu Osaki, Hitoshi Nakano, Jun Ichi Maruyama, Hideaki Omiya, Tetsuo Shimizu, Hirotaka Hashizume, Yuka Fujita, Yutaka Nishigaki, Tadakatsu Tsuji, Satoru Tanasawa, Satoshi Koyama, Akira Saito, Kazuo Takebe, Yuichi Hirai, Kazuki KonishiHiroshi Inoue, Kenichi Takeuchi, Masashi Tamura, Toshihiro Nukiwa, Akira Watanabe, Yushi Nakai, Yoshihiro Honda, Shigeo Takizawa, Kenji Yanagise, Mikae Nakamura, Shoko Tagami, Kohya Shiba, Osamu Sakai, Kazuhisa Okada, Kaoru Shimada, Yasuyuki Sano, Yasuo Arai, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Kihachiro Shimizu, Yukio Suzuki, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Kenichi Takahashi, Yasuhiro Yoshiike, Takashi Ogura, Yoshihiro Hirai, Tadashi Akahori, Hidekazu Kitamura, Yuriko Ishimaru, Satoshi Inoue, Takao Okubo, Hirotada Ikeda, Hiroshi Matsumoto, Shoichiro Irimajiri, Yasuo Matsuoka, Yasuo Osone, Masaaki Arakawa, Kohichi Wada, Shigeyuki Hoshino, Akira Iwashima, Fumihide Iwata, Hiroyuki Sega, Samu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Atsuro Honda, Toshihiko Hasizume, Atsuhiko Sato, Kingo Chida, Shiro Imokawa, Masatoshi Iwata, Rinko Kita, Masaaki Ida, Yutaka Nakano, Takayoshi Watanabe, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Hidekazu Hanaki, Makoto Kawakami, Shinji Takeyama, Yuji Usami, Hideaki Kuroki, Tomoyuki Tashiro, Ryuji Nomura, Fumio Miki, Eiro Tsubura, Tomio Masuno, Masaru Nakagawa, Toshihiko Yamaguchi, Yoshihiro Takishita, Hiroyasu Bando, Yoshihiro Suzuki, Nobuhiro Narita

Research output: Contribution to journalArticlepeer-review

Abstract

The clinical efficacy, safety and usefulness of cefoselis (FK 037, CFSL), a new parenteral cephalosporin, were evaluated in chronic respiratory tract infection in a comparative study with ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days. The following results were obtained. 1. A total of 167 patients were enrolled in this study. Efficacy rates ('good' and better responses) were 90.3% (65/72) in the CFSL group and 89.7% (61/68) in the CAZ group. 2. Bacteriological effects (eradication rates) were 89.2% (33/37) in the CFSL group and 94.1% (32/34) in the CAZ group. 3. Adverse reactions occurred in 6 of the 81 patients in the CFSL group and in 2 of the 76 patients in the CAZ group. The incidence of abnormal laboratory findings was 11.1% (9/81) in the CFSL group and 13.3% (10/75) in the CAZ group. 4. Usefulness rates ('useful' and better responses) were 84.9% (62/73) in the CFSL group and 86.8% (59/68) in the CAZ group. No significant difference was observed between the two groups in any of the above items. The results indicate that cefoselis is a useful drug in the treatment of chronic respiratory tract infections. This paper reports clinical results excluding cases violating Good Clinical Practice (GCP) found after publication of our previous paper in 'Jpn. J. Chemother.' (Vol. 43, No. 4, 1995).

Original languageEnglish
Pages (from-to)527-544
Number of pages18
JournalJapanese Journal of Chemotherapy
Volume44
Issue number7
Publication statusPublished - 1996 Jul
Externally publishedYes

Keywords

  • cefoselis
  • ceftazidime

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A comparative study of cefoselis and ceftazidime in chronic respiratory tract infections'. Together they form a unique fingerprint.

Cite this